Neurotech International Limited

NTI

AU000000NTI9

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 09:55:54 30/05/2024 am IST			5-day change	1st Jan Change
0.072 ^AUD	-1.37%		-4.00%	+4.35%

17/04	Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint	MT
17/04	Neurotech International Completes AU$10 Million Capital Raise	MT

Neurotech International Limited Announces Passing of Professor Allan Cripps AO, Non-Executive Director

December 21, 2022 at 04:42 am IST

Neurotech International Limited announced the passing of Professor Allan Cripps AO, Non-Executive Director and Chief Scientist of the Company.

Latest news about Neurotech International Limited

Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint	17/04	MT
Neurotech International Completes AU$10 Million Capital Raise	17/04	MT
Neurotech International Concludes Phase II/III NTIASD2 Trial for Children with Autism	10/04	MT
Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27/02	CI
Neurotech Receives Human Research Ethics Committee Approval to Extend Autism Trial	13/02	MT
Neurotech's ASD Drug Trials Exceed 90 Weeks	07/02	MT
Neurotech International Secures Approval to Advance Cerebral Palsy Trial; Shares Rise 6%	29/01	MT
Neurotech International Completes Enrolment for Phase 2/3 Autism Spectrum Trial	19/12	MT
Neurotech International Secures Ethics Approval for Use of Autism Spectrum Medication in Adults	04/12	MT
Neurotech International Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023	14/11	MT
Neurotech International Completes Enrollment for Rett Syndrome Trial	26/23/26	MT
Neurotech International Completes Treatment for Last Patient in Phase I/II PANDAS/PANS Clinical Trial	31/23/31	MT
Neurotech International Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/23/30	CI
Neurotech International Secures Ethics Approval for Clinical Trial of Neurological Medication	10/23/10	MT
Neurotech International Secures Ethics Approval to Extend Use of Medication in Pediatric Trial	30/23/30	MT
Neurotech International Completes Patient Recruitment for Neuropsychiatric Disorder Treatment Trial	03/23/03	MT
Neurotech International Plans to Launch Phase Two Rett Syndrome Trial	20/23/20	MT
Neurotech International Limited Announces the Launch of A New Clinical Program in Rett Syndrome, Commencement of A Phase II Clinical Trial Investigating the Use of NTI164 in Female Patients	20/23/20	CI
Neurotech International Says Considerable Improvement in ASD Patients Treated with NTI164; Shares Decline 9%	17/23/17	MT
Neurotech International Limited Announces the Final Clinical Results from Eleven Paediatric Autism Spectrum Disorder Patients, Following Daily Treatment of NTI164 over 52 Week Period	17/23/17	CI
Neurotech International Halts Trade Pending Release of Clinical Trial Data	15/23/15	MT
Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2022	28/23/28	CI
Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial	16/23/16	CI
Neurotech International Secures Ethics Approval to Extend Phase 1/2 Autism Trial	14/23/14	MT
Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension	14/23/14	CI

Chart Neurotech International Limited

Duration

Period

More charts

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.

Sector

Biotechnology & Medical Research

Calendar

28/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NEUROTECH INTERNATIONAL LIMITED	+4.35%	49.17M
MODERNA, INC.	+52.36%	56.69B
IQVIA HOLDINGS INC.	-3.86%	41B
LONZA GROUP AG	+38.14%	38.11B
CELLTRION, INC.	-12.01%	26.89B
ICON PUBLIC LIMITED COMPANY	+14.13%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-21.62%	18.59B
BIO-TECHNE CORPORATION	+0.21%	12.39B
MEDPACE HOLDINGS, INC.	+25.96%	11.99B
UNITED THERAPEUTICS CORPORATION	+23.02%	11.88B